Research ArticleSystemic Lupus Erythematosus

Improvement of Outcomes in Patients with Lupus Nephritis: Management Evolution in Chinese Patients from 1994 to 2010

Si-Jia Shao, Jin-Hua Hou, Guo-Tong Xie, Wen Sun, Dan-Dan Liang, Cai-Hong Zeng, Hui-Xian Zhu and Zhi-Hong Liu
The Journal of Rheumatology August 2019, 46 (8) 912-919; DOI: https://doi.org/10.3899/jrheum.180145

REFERENCES

  1. 1.↵
    1. Bernatsky S,
    2. Boivin JF,
    3. Joseph L,
    4. Manzi S,
    5. Ginzler E,
    6. Gladman DD,
    7. et al.
    Mortality in systemic lupus erythematosus. Arthritis Rheum 2006;54:2550–7.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Donadio JV Jr,
    2. Hart GM,
    3. Bergstralh EJ,
    4. Holley KE
    . Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus 1995;4:109–15.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Bono L,
    2. Cameron JS,
    3. Hicks JA
    . The very long-term prognosis and complications of lupus nephritis and its treatment. Q J Med 1999;92:211–8.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Kono M,
    2. Yasuda S,
    3. Kato M,
    4. Kanetsuka Y,
    5. Kurita T,
    6. Fujieda Y,
    7. et al.
    Long-term outcome in Japanese patients with lupus nephritis. Lupus 2014;23:1124–32.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Yang J,
    2. Liang D,
    3. Zhang H,
    4. Liu Z,
    5. Le W,
    6. Zhou M,
    7. et al.
    Long-term renal outcomes in a cohort of 1814 Chinese patients with biopsy-proven lupus nephritis. Lupus 2015;24:1468–78.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Mok CC,
    2. Kwok RC,
    3. Yip PS
    . Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum 2013;65:2154–60.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Chan TM
    . Treatment of severe lupus nephritis: the new horizon. Nat Rev Nephrol 2015;11:46–61.
    OpenUrlPubMed
  8. 8.↵
    1. Austin HA 3rd,
    2. Klippel JH,
    3. Balow JE,
    4. le Riche NG,
    5. Steinberg AD,
    6. Plotz PH,
    7. et al.
    Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614–9.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Chan TM,
    2. Li FK,
    3. Tang CS,
    4. Wong RW,
    5. Fang GX,
    6. Ji YL,
    7. et al.
    Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000;343:1156–62.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Austin HA 3rd,
    2. Illei GG,
    3. Braun MJ,
    4. Balow JE
    . Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 2009;20:901–11.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Chen W,
    2. Tang X,
    3. Liu Q,
    4. Chen W,
    5. Fu P,
    6. Liu F,
    7. et al.
    Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis 2011;57:235–44.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Bao H,
    2. Liu ZH,
    3. Xie HL,
    4. Hu WX,
    5. Zhang HT,
    6. Li LS
    . Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol 2008;19:2001–10.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Liu ZH,
    2. Zhang HT,
    3. Liu ZS,
    4. Xing CY,
    5. Fu P,
    6. Ni Z,
    7. et al.
    Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med 2015;162:18–26.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Rovin BH,
    2. Furie R,
    3. Latinis K,
    4. Looney RJ,
    5. Fervenza FC,
    6. Sanchez-Guerrero J;
    7. LUNAR Investigator Group
    . Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012;64:1215–26.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. ACCESS Trial Group
    . Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. Arthritis Rheum 2014;66:3096–104.
    OpenUrlCrossRef
  16. 16.↵
    1. Korbet SM,
    2. Lewis EJ,
    3. Schwartz MM,
    4. Reichlin M,
    5. Evans J,
    6. Rohde RD
    . Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 2000;35:904–14.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Davidson A
    . What is damaging the kidney in lupus nephritis? Nat Rev Rheumatol 2016;12:143–53.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Ward MM
    . Medical insurance, socioeconomic status, and age of onset of endstage renal disease in patients with lupus nephritis. J Rheumatol 2007;34:2024–7.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Weening JJ,
    2. D’Agati VD,
    3. Schwartz MM,
    4. Seshan SV,
    5. Alpers CE,
    6. Appel GB,
    7. et al.
    The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15:241–50.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Cattran DC,
    2. Feehally J,
    3. Cook HT,
    4. Liu ZH,
    5. Fervenza FC,
    6. Mezzano SA,
    7. et al;
    8. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group
    . KDIGO clinical practice guidelines for glomerulonephritis. Kidney Int Suppl 2012;2:139–274.
    OpenUrlCrossRef
  21. 21.↵
    1. Fiehn C,
    2. Hajjar Y,
    3. Mueller K,
    4. Waldherr R,
    5. Ho AD,
    6. Andrassy K
    . Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann Rheum Dis 2003;62:435–9.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Faurschou M,
    2. Dreyer L,
    3. Kamper AL,
    4. Starklint H,
    5. Jacobsen S
    . Long-term mortality and renal outcome in a cohort of 100 patients with lupus nephritis. Arthritis Care Res 2010;62:873–80.
    OpenUrlCrossRef
  23. 23.↵
    1. Croca SC,
    2. Rodrigues T,
    3. Isenberg DA
    . Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology 2011;50:1424–30.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Yap DY,
    2. Tang CS,
    3. Ma MK,
    4. Lam MF,
    5. Chan TM
    . Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant 2012;27:3248–54.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Moroni G,
    2. Quaglini S,
    3. Gallelli B,
    4. Banfi G,
    5. Messa P,
    6. Ponticelli C
    . Progressive improvement of patient and renal survival and reduction of morbidity over time in patients with lupus nephritis (LN) followed for 20 years. Lupus 2013;22:810–8.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Sexton DJ,
    2. Reule S,
    3. Solid C,
    4. Chen SC,
    5. Collins AJ,
    6. Foley RN
    . ESRD from lupus nephritis in the United States, 1995–2010. Clin J Am Soc Nephrol 2015;10:251–9.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Korbet SM,
    2. Schwartz MM,
    3. Evans J,
    4. Lewis EJ;
    5. Collaborative Study Group
    . Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol 2007;18:244–54.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Mok MY,
    2. Li WL
    . Do Asian patients have worse lupus? Lupus 2010;19:1384–90.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Walsh SJ,
    2. DeChello LM
    . Geographical variation in mortality from systemic lupus erythematosus in the United States. Lupus 2001;10:637–46.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Barr RG,
    2. Seliger S,
    3. Appel GB,
    4. Zuniga R,
    5. D’Agati V,
    6. Salmon J,
    7. et al.
    Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol Dial Transplant 2003;18:2039–46.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Karlson EW,
    2. Daltroy LH,
    3. Lew RA,
    4. Wright EA,
    5. Partridge AJ,
    6. Roberts WN,
    7. et al.
    The independence and stability of socioeconomic predictors of morbidity in systemic lupus erythematosus. Arthritis Rheum 1995;38:267–73.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Hu S,
    2. Tang S,
    3. Liu Y,
    4. Zhao Y,
    5. Escobar ML,
    6. de Ferranti D
    . Reform of how health care is paid for in China: challenges and opportunities. Lancet 2008;372:1846–53.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Meng Q,
    2. Xu L,
    3. Zhang Y,
    4. Qian J,
    5. Cai M,
    6. Xin Y,
    7. et al.
    Trends in access to health services and financial protection in China between 2003 and 2011: a cross-sectional study. Lancet 2012;379:805–14.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Hu WX,
    2. Liu ZH,
    3. Chen HP,
    4. Tang Z,
    5. Wang QW,
    6. Shen KQ,
    7. et al.
    Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J 2002;115:705–9.
    OpenUrlPubMed
  35. 35.↵
    1. F L,
    2. Y T,
    3. X P,
    4. L W,
    5. H W,
    6. Z S,
    7. et al;
    8. MMF in Induction Therapy for Active Lupus Nephritis in Mainland China Study Group
    . A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis. Lupus 2008;17:622–9.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Houssiau FA,
    2. Vasconcelos C,
    3. D’Cruz D,
    4. Sebastiani GD,
    5. de Ramon Garrido E,
    6. Danieli MG,
    7. et al.
    Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004;50:3934–40.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Parikh SV,
    2. Nagaraja HN,
    3. Hebert L,
    4. Rovin BH
    . Renal flare as a predictor of incident and progressive CKD in patients with lupus nephritis. Clin J Am Soc Nephrol 2014;9:279–84.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Giatras I,
    2. Lau J,
    3. Levey AS
    . Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med 1997;127:337–45.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Kanda H,
    2. Kubo K,
    3. Tateishi S,
    4. Sato K,
    5. Yonezumi A,
    6. Yamamoto K,
    7. et al.
    Antiproteinuric effect of ARB in lupus nephritis patients with persistent proteinuria despite immunosuppressive therapy. Lupus 2005;14:288–92.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

 Request Permissions

Save to my folders

Jump to section

Keywords

LUPUS NEPHRITIS
REMISSION
OUTCOMES

Keywords